Back to News
Market Impact: 0.25
InnoCare Gets China CDE Nod For Phase 3 Mesutoclax Combo Trial In Lymphoma
Source: Nasdaq
Healthcare & Biotech
InnoCare Pharma received China NMPA Center for Drug Evaluation approval to initiate a Phase 3 clinical trial of mesutoclax in combination with another therapy; the article text is cut off before naming the partner treatment. The trial authorization is a positive development milestone, but no efficacy results or further trial details are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Alaunos completes Velaris acquisition, raises $350 million